Among new users, rates of recurrent venous thromboembolism, GI and intracranial bleeding lower with apixaban than rivaroxaban
Improved communication with patients about cost, bleeding, and monitoring may increase compliance
Apixaban the only direct oral anticoagulant linked to lower adverse event rates than warfarin for patients with atrial fibrillation across frailty levels
Direct oral anticoagulants reduce recurrent VTE events by 41 percent, with no significant increase in major bleeding, compared to dalteparin
Major adverse cardiopulmonary outcomes not reduced with aspirin, apixaban versus placebo for clinically stable COVID-19 outpatients
Compared with other DOACs, rivaroxaban linked to higher rates of GI bleeding overall and in an analysis restricted to patients with atrial fibrillation
Disparities seen among VA patients both for initiating any anticoagulant therapy and for initiating direct-acting oral anticoagulant use
